INXMED

InxMed is a clinical-stage biotech company established in the end of 2018. The company dedicates on developing innovative therapies targeting stroma microenvironment and solid tumor resistance and metastasis, especially new drug development on anti PD-1/PD-L1 treatment drug resistance. InxMed committees to building an efficient engine for clinical translational science and proof of concept platform driven by in-depth understanding of disease biology and is committed to becoming a global leader in revolutionary cancer therapies... InxMed-Biotech company-Drug discovery-Founded in 2018, InxMed is a clinical-stage oncology focused biotech company with a winning strategy of "Best-in-Disease Combination". With disease biology being the source of innovation, the company aims to find solutions for oncology drug resistance and tumor metastasis, especially resistance to anti-PD-1... With in-depth knowledge of disease biology at the core of our innovation, InxMed is committed to becoming a..

Also known as: InxMed (Beijing) Co., Ltd., InxMed (Nanjing) Co., Ltd., Inxmed Co. Ltd.

Primary location: Nanjing